Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Shares Outstanding (Weighted Average) (2016 - 2018)

BeOne Medicines (BEIGF) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $720.8 million as the latest value for Q4 2018.

  • Quarterly Shares Outstanding (Weighted Average) rose 32.69% to $720.8 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $720.8 million through Dec 2018, up 32.69% year-over-year, with the annual reading at $720.8 million for FY2018, 32.69% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2018 was $720.8 million at BeOne Medicines, up from $698.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $720.8 million in Q4 2018, with the low at $107.0 million in Q3 2015.
  • Average Shares Outstanding (Weighted Average) over 4 years is $406.1 million, with a median of $403.6 million recorded in 2016.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 264.95% in 2016, then grew 29.83% in 2018.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $110.6 million in 2015, then surged by 264.95% to $403.6 million in 2016, then soared by 34.58% to $543.2 million in 2017, then soared by 32.69% to $720.8 million in 2018.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $720.8 million, $698.5 million, and $670.5 million for Q4 2018, Q2 2018, and Q1 2018 respectively.